Telacebec clinical trials
Also written Q203.
How each study uses telacebec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the telacebec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Studies
Open first, then newest update. How each study uses telacebec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)RecruitingPhase 2Barwon HealthNCT06481163Written as Telacebec
- A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 PatientsTerminatedPhase 2Qurient Co., Ltd.NCT04847583Written as Telacebec
- A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)CompletedPhase 2Qurient Co., Ltd.NCT03563599Written as Telacebec (Q203)
- A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female VolunteersCompletedPhase 1Qurient Co., Ltd.NCT02858973Written as Q203
- A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female VolunteersCompletedPhase 1Qurient Co., Ltd.NCT02530710Written as Q203
Codes
What other systems call telacebec · ClinicalTrials.gg INT006375
- MeSH (NLM) C584497telacebecOne source NLM
- UNII (FDA) 55G92WGH3XTELACEBECConfirmed FDA, NLM, Wikidata
- Wikidata Q27261307telacebecConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152543TelacebecOne source FDA
- DrugBank DB17754One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584497 | telacebec | One source NLM |
| UNII (FDA) | 55G92WGH3X | TELACEBEC | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27261307 | telacebec | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152543 | Telacebec | One source FDA |
| DrugBank | DB17754 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.